Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR. T regulatory and primed uncommitted CD4 T
cells express CD73, which suppresses effector CD4 T cells by converting 5’-adenosine monophosphate to
adenosine. J Immunol. 2006;177(10):6780-6786.
Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory
T cells mediates immune suppression. J Exp Med. 2007;204(6):1257-1265.
Picher M, Burch LH, Hirsh AJ, Spychala J, Boucher RC. Ecto 5’-nucleotidase and nonspecific alkaline
phosphatase. J Biol Chem. 2003;278(15):13468-13479.
Häusler SF, del Barrio IM, Strohschein J, et al. Ectonucleotidases CD39 and CD73 on OvCA cells are potent
adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function
and NK cell cytotoxicity. Cancer Immunol Immunother. 2011;60(10):1405-1418.
Serra S, Horenstein AL, Vaisitti T, et al. CD73-generated extracellular adenosine in chronic lymphocytic
leukemia creates local conditions counteracting drug-induced cell death. Blood. 2011;118(23):6141-6152.
Ohta A, Gorelik E, Prasad SJ, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc
Natl Acad Sci USA. 2006;103(35):13132-13137.
Stagg J, Divisekera U, McLaughlin N, et al. Anti-CD73 antibody therapy inhibits breast tumor growth and
metastasis. Proc Natl Acad Sci USA. 2010;107(4):1547-1552.
Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and
anti-CTLA-4 mAbs. Clin Cancer Res. 2013;19(20):5626-5635.